Breast translational research has markedly evolved over the past few decades and the emerging knowledge has revolutionized our understanding of breast neoplasms. Novel techniques and concepts in studying breast cancer have been developed. These have contributed to the understanding and recognition of this complex disease.

This special topic issue on *Breast Translational Research* provides pertinent and succinct reviews on tumor microenvironment, metabolomics, the role of the calpain family of enzymes, the molecular mechanisms of lymphovascular invasion, and predictors of response to neoadjuvant therapy. It proposes and illustrates a new terminology for the practising pathologist who needs to describe a diagnostically challenging group of breast neoplasms showing dermal analogue differentiation. It also evaluates the role of p40 immunohistochemistry in diagnostic breast pathology.

This publication is of special interest to pathologists as well as scientists and members of the breast multidisciplinary team, since it provides a useful overview of pertinent markers and techniques in the field of breast cancer translational research and diagnostic histopathology.

**Contents**

**Editorial**
- Breast Translational Research: Past, Present and Future: Shaaban, A.M.

**Invited Review**
- Molecular Mechanisms Underlying Lymphovascular Invasion in Invasive Breast Cancer: Aleskandarany, M.A.; Sonbul, S.N.; Mukherjee, A.; Rakha, E.A.
- Calpain in Breast Cancer: Role in Disease Progression and Treatment Response: Storr, S.J.; Thompson, N.; Pu, X.; Zhang, Y.; Martin, S.G.
- Role of the Tumor Microenvironment in Breast Cancer: Soysal, S.D.; Tzankov, A.; Muenst, S.E.
- Metabolomic Biomarkers for Breast Cancer: Guenther, U.L.

**Original Paper**

**Novel Insights from Research Practice**

Author Index/Subject Index

**Dear Librarian**

I have reviewed this publication and would like to recommend it for our library.

Recommended by:

Department:

Date:

Signature:

Orders may be placed with any bookshop, subscription agency, directly with the publisher or through a Karger distributor.

The easiest way to order: [www.karger.com/pat](http://www.karger.com/pat)
Guidelines for Authors

Submission
Before submission, please read the Guidelines for Authors for specific requirements for manuscript preparation. Manuscripts written in English are considered and should be submitted online at www.karger.com/che (a link leads you to the Submission Website).

Submission of an article implies author agreement with the below Conditions. To be considered for publication, all manuscripts must be accompanied by a cover letter signed by all authors stating that the work has not been published, nor is it under consideration elsewhere, and that all authors approve the submission.

A Copyright Transfer Form, available on the Submission Website, with the corresponding author’s original (handwritten) signature must be received by the editorial office. Please print and sign the form, and upload it during submission (or fax or scan and email) to make it legally binding.

Names, postal and e-mail addresses of 4 international experts in the appropriate area of research should accompany each manuscript. At the Editors’ discretion, scientist(s) selected from this list may be invited to act as referee(s). Referees suggested should not be from the same institution as the author.

Presentation of manuscripts should follow the Uniform Requirements for Manuscripts Submitted to Biomedical Journals [see International Committee of Medical Journal Editors. Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication (April 2010). Available from: http://www.icmje.org].

In case of problems with submission, please contact:
che@karger.com
S. Karger AG - Medical and Scientific Publishers
Editorial Office ‘Chemotherapy’
Allschwilerstrasse 10
CH-4009 Basel (Switzerland)
Tel. +41 61 306 1361
Fax +41 61 306 1434

Conditions
All manuscripts are subject to editorial and peer review. Manuscripts are received with the explicit understanding that the work has not been published (wholly or in part), and is not under simultaneous consideration in any language elsewhere. Furthermore, all authors have made substantial contributions and confirm that they have seen and approve the manuscript submission. Submission of an article for publication implies the transfer of the copyright from the author to Karger Publishers upon acceptance. Accepted papers become the permanent property of Karger Publishers. The full postal address, telephone and fax numbers, as well as the e-mail address of the author to whom correspondence should be sent must be given at the bottom of the title page.

Ethics
Research must comply with the guidelines for human studies and animal welfare regulations. Manuscripts reporting studies on human subjects should include evidence that the research was ethically conducted in accordance with the Declaration of Helsinki (World Medical Association; http://www.wma.net/en/30publications/10policies/b3/index.html). In particular, authors should state in the Materials and Methods section that subjects have given their informed written consent and that the study protocol was approved by an appropriate ethics committee. All patients should be identified by numbers or aliases, not by their real names. Authors should also state that animal experimen-
tation was approved by an independent ethics committee. Copies of these guidelines and policy statements must be available for review by the editors if necessary.

Plagiarism Policy
Whether intentional or not, plagiarism is a serious viola-
tion. Karger Publishers defines plagiarism as reproduction of another work with at least 25% similarity and without citation. If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).

Sections
Authors should indicate in the cover letter which manuscript type is being submitted for publication:

Original Papers: Fully documented reports of original research that must describe full sets of significant, original experiments in current anti-infective and antimumor chemotherapy research. Abstract, Introduction, Materials and Methods, Results, and Discussion sections are required. Consideration for publication is based on originality, novelty, scientific soundness, and appropriate analysis (maximum 3,000 words, 80 references, plus tables/figures).

Reviews: Comprehensive, state-of-the-art papers cover-
ing a timely topic by experts in the field (maximum 4,000 words, plus tables/figures, references). Reviews are usually invited by the Editor but may be unsolicited. Authors are asked to contact the Editor-in-Chief before submission in order to avoid clashes with other pending reviews. All reviews are subject to peer review. An unstructured abstract of no more than 200 words is required.

Novel Insights from Clinical Practice: The journal only con-
siders case reports that provide significant new insights into a clinical problem or with an extremely unusual clinical course. Submissions can be based around a case or a number of similar cases. The most important aspect of the presenta-
tion is that it should provide a new perspective on a recognized clinical scenario or may represent an entirely new clinical condition. The novel aspects of the case(s) may be in the phenotype, the presentation, the investigation and/or the management. The manuscript should contain an unstructured abstract (maximum 150 words), introduction, case report and discussion section (maximum 2,000 words, maximum 2 tables or figures). Boxes containing bul-
let points on Established Facts (what is already known) and Novel Insights (new information gained) are required on the first page of the report. These should highlight the nov-
ety of the clinical observation.

Short Communications: Short reports, brief laboratory ob-
servations, and preliminary communications can be sub-
mitted for accelerated publication under Short Commu-
nications. They must present new findings of sufficient importance to justify their accelerated acceptance. Such communications should represent complete, original stud-
ies and should be arranged in the same way as full length manuscripts (maximum 1,600 words).

Letters to the Editor: Letters to the Editor are encouraged if they directly concern articles recently published in this journal. If accepted, the Editor reserves the right to submit such letters to the authors of the articles concerned prior to publication in order to allow them to respond in the same issue of the journal. In exceptional cases, Letters to the Edi-
tor may also address data published in another journal or general subjects related to matters discussed in the journal. No abstract is required (maximum 1,200 words).

Arrangement
The preferred word processing program is MS-Word. The cover letter, the manuscript, the tables and the figures must be submitted in separate files. The manuscript file must contain all the text elements in the following order: title page, abstract and key words, main text, acknowledg-
ments, references, figure and table legends. Tables and fig-
ures should be submitted as separate files according to the instructions below. Automatic line numbering should be used consecutively from the title page through to the final page. All pages should be numbered, starting from the title page, including tables, figure legends and figures.

Title page: The first page should contain the concise title of the article along with a short title for use as a running head, the full names of the authors and their affiliations (department, institute, hospital, university etc. where the work was conducted). The full postal address, telephone and fax numbers, as well as the e-mail address of the author to whom correspondence should be sent must be given at the bottom of the title page.

Key words: Please supply 3–10 key words that reflect the content of the paper.

Abstract: Each original paper needs an abstract of up to 250 words structured with subheadings as follows: Back-
ground/Aims, Methods, Results, Conclusion. Structured abstracts are not needed for Reviews and Novel Insights from Clinical Practice.

Footnotes: Footnotes should be avoided. When essential, they should be numbered consecutively and appear at the foot of the appropriate page.

Acknowledgements: Include all sources of funding for the research presented in the manuscript and substantive con-
tributions of individuals regarding the research or man-
uscript. All possible conflicts of interest should also be given here.

Abbreviations: Abbreviations (with the exception of those clearly well-established in the field) should be explained when they are first used.

Units of measurement: Measurements should be expressed in SI units wherever possible.

Drug names: Use generic names of drugs (first letter: lower-
case) whenever possible. Registered trade names (first letter: uppercase) should be marked with the superscript registration symbol ® or ™ when they are first mentioned.

Tables and illustrations: Tables and figures must be num-
bered (e.g. Figure 1, Figure 2) and submitted as separate files. Tables require a heading and figures a legend, which must provide sufficient information for either to stand alone. Each figure and table must be cited in the text nu-
merically. Tables should be in Word format. b/w half-tone and color figures must have a minimum resolution of 300 dpi a-ter scaling to final size, line drawings 1200 dpi. Color figures must be in RGB format. All figures should be in a common format such as PDF, TIF, PNG, EPS or WMF. Vector graph-
ics should be in PPT, AI or EPS format.
Color Illustrations

Online edition: Color figures are reproduced free of charge. In the print version, the figures are reproduced in black and white. For figures, the colors in the text and figure legends should be avoided.

Print edition: Up to 6 color figures per page can be integrated within the text at CHF 960.00 per page.

References

Identity references in the text using Arabic numerals [in square brackets]. Do not alphabetize; number references sequentially in the order cited in the text. Material submitted for publication but not yet accepted should be referred to as [unpublished data] and should not be included in the reference list. A reference list should include only those publications which are cited in the text. Authors' surnames should be followed by their initials with no punctuation other than a comma to separate individual authors. Preferably cite all authors (if not possible include at least 3 authors followed by et al). Abbreviate journal names according to the list of journals indexed for MEDLINE on the NLM website. Also see International Committee of Medical Journal Editors: Uniform Requirements for Manuscripts Submitted to Biomedical Journals (http://www.ICMJE.org).

Examples


Reference Management Software: The use of EndNote is recommended to facilitate formatting of citations and reference lists. The journal output style can be downloaded from http://endnote.com/downloads/styles.

Supplementary Material and Multimedia Files

Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Multimedia files enhance the online version of a publication. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 MB in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, avi, mp4).

English Language Editing

For authors whose native language is not English, use of a professional language editing service prior to submission can help to avoid delays with the review process.

Digital Object Identifier (DOI)

A DOI number will be available as a unique identifier on the title page of each article. DOIs are useful for identifying and citing articles published online without volume or issue information (for more information, see www.doi.org).

Self-Archiving/Green Open Access

Karger permits authors to archive their pre-prints (i.e. peer review) or post-prints (i.e. accepted manuscript after peer review but before production) on their personal or their institution’s internal website. In addition, authors may post their accepted manuscripts in public Open Access repositories and scientific networks (e.g. ResearchGate or Mendeley) no earlier than 12 months following publication of the final version of their article. For all self-archiving, the posted manuscripts must:

• Be used for noncommercial purposes only
• Be linked to the final version on www.karger.com

Include the following statement:

‘This is the peer-reviewed but unedited manuscript version of the following article: [insert full citation, e.g. Cytogenet Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)].’

It is the author’s responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

Manuscripts to be archived in PubMed Central due to funding requirements will be submitted by Karger on the author’s behalf (see Funding Organizations (NIH etc.)).

For self-archiving Author’s Choice articles, see Author’s Choice.

Author’s Choice

Karger’s Author’s Choice service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/author_choice.

The final, published version of the article may be posted at any time and in any repository or on other websites, in accordance with the relevant Creative Commons license. Reposted Open Access articles must:

• Follow the terms of the relevant Creative Commons license
• Be linked to the final version on www.karger.com
• Include the following statement:

‘The final, published version of this article is available at http://www.karger.com/[doi] (insert DOI number).’

It is the author’s responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

Funding Organizations (NIH etc.)

The U.S. National Institutes of Health (NIH) Public Access Policy mandates that accepted, peer-reviewed manuscripts are archived in its digital database, PubMed Central (PMC), within 12 months of the official publication date. As a service to authors, Karger submits NIH-funded articles to PMC on behalf of the authors immediately upon publication. The NIH assigns a PMCID within approximately 1 month and the manuscript will appear in PMC after a 12-month embargo. For authors making their paper Open Access through Author’s Choice, the embargo will be overridden, thereby accelerating the accessibility of the article. Karger also complies with other funders’ requirements (including Wellcome Trust and RCUK) for submission to PMC. Authors should include information on their grants in the Acknowledgements section of their papers.

Copy Editing

Manuscripts accepted for publication by Karger Publishers are subject to copy editing.

Proofs

An email containing a link to download the proofs will be sent to the corresponding author. Proofs should be returned within 48 hours. Alterations made in proofs, other than the correction of printer’s (introduced) errors, are charged to the author and may require editorial approval.

Page Charges

There is no page charge for papers of 3 or fewer printed pages (including tables, illustrations and references). Authors are charged CHF 325.00 for each additional complete or partial printed page.

Reprints

An order form with a price list can be requested when returning the corrected proofs. Orders submitted after the issue is printed are subject to considerably higher prices.
Disclaimers: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements and/or products referred to in the content or advertisements does not constitute endorsement. The publisher, its agents and employees and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Subscription Orders:
Orders can be placed at agencies, bookstores, directly with the Publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.

Change of Address:
Both old and new address should be sent to the subscription source.

Photo of Paul Ehrlich on inner title page
Courtesy of the Paul-Ehrlich-Institute, Langen, Germany
48th Congress of the International Society of Paediatric Oncology

October 19 - 22, 2016
www.kenes.com/siop

REGISTER TODAY
A new approach to treating AYA with hematological malignancies

Adolescents and Young Adults with Hematological Disorders

Challenges and Perspectives

Editors
Martin S. Tallman
Pia Raanani

The distinct biology of hematological disorders as well as other age-related issues in adolescent and young adult (AYA) patients deserves unique psychological and medical attention. It emphasizes the necessity for a treatment approach taking into consideration their special needs. These include fertility considerations, survivorship issues, psychological support, adherence to treatment difficulties and other dilemmas and problems exclusive to this group of patients. AYA patients may usually better support intensive treatments and if possible should be referred to special centres and participate in clinical trials. In recent years the focus on AYA patients in oncology and hemato-oncology has increased. Still a distinct approach to these patients is an unmet need. This special issue tries to increase awareness for this group of patients as well as to cover the wide spectrum of hematological disorders that is pertinent to AYA patients who face special therapeutic challenges. This publication is of interest for physicians dealing with AYA, especially in the field of hematology and oncology, as well as other age-related issues in adolescent and young adults: present and future.

Contents
• The Challenges and Perspectives in Treating Adolescent and Young Adult Patients with Hematological Disorders: Raanani, P.; Tallman, M.S.
• Acute Lymphoblastic Leukemia in Adolescents and Young Adults: Burke, P.W.; Douer, D.
• The Challenging Aspects of Managing Adolescents and Young Adults with Hodgkin's Lymphoma: Jachimowicz, R.D.; Engert, A.
• Adolescents and Young Adults with Non-Hodgkin's Lymphoma: Slipping between the cracks: Wolach, O.; Ram, R.
• Acute Myeloid Leukemia in Adolescents and Young Adults: Challenging Aspects: Ofman, Y.; Rowe, J.M.
• Chronic Myeloid Leukemia in Adolescents and Young Adults: Patient Characteristics, Outcomes and Review of the Literature: Pemmaraju, N.; Cortes, J.
• Acute Promyelocytic Leukemia in Children and Adolescents: Stein, E.M.; Tallman, M.S.
• Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults: Tewari, P.; Franklin, A.R.; Terek, N.; Askins, M.A.; Mofield, S.; Kebraili, P.
• Challenging Aspects of Managing Hemostasis in Adolescents: Nowak-Götti, U.; Kenet, G.
• Aplastic Anemia in Adolescents and Young Adults: DeZern, A.E.; Guinan, E.C.
• Thalassemia Major and Sickle Cell Disease in Adolescents and Young Adults: Yacobovich, J.; Tamary, H.
• Acute Myeloid Leukemia in Adolescents and Young Adults: Challenges for Cancer Care Delivery to Adolescents and Young Adults: Present and Future: Meeneghan, M.R.; Wood, W.A.

Dear Librarian
I have reviewed this publication and would like to recommend it for our library.

Recommended by:

Department:

Date:

Signature:

Orders may be placed with any bookseller, subscription agency, directly with the publisher or through a Karger distributor.

The easiest way to order: www.karger.com/aha

Karger – Medical and Scientific Publishers
CH-4009 Basel, Switzerland
orders@karger.com, T +41 61 306 12 34
www.karger.com

Karger 125th
Emerging Strategies for the Management of Hepatocellular Carcinoma

The 4th International Kyoto Liver Cancer Symposium (4th IKLS)

Editor
M. Kudo

Contents

Preface
- Emerging Strategies for the Management of Hepatocellular Carcinoma: Kudo, M.

Original Articles
- Epidemiological Trends of Hepatocellular Carcinoma in Austria: Pinter, M.; Hucke, F.; Zielonke, N.; Trauner, M.; Sieghart, W.; Peck-Radosavljevic, M.

Review Articles
- Ultrasound Fusion Imaging of Hepatocellular Carcinoma: A Review of Current Evidence: Minami, Y.; Kudo, M.
- Focal Lesions in the Cirrhotic Liver: Their Pivotal Role in Gadobitic Acid-Enhanced MRI and Recognition by the Western Guidelines: Goffi, R.; Garzillo, G.; Ascanio, S.; Renzulli, M.

Original Articles

Review Articles
- Adjuvant Therapy for Hepatocellular Carcinoma after Curative Treatment: Jeng, W.-J.; Lin, C.-C.; Chen, W.-T.; Sheen, I.-S.; Lin, C.-Y.; Lin, S.-M.
- Considerations for Radiation Therapy in Hepatocellular Carcinoma: The Radiation Oncologist’s Perspective: Yu, J.J.; Park, H.C.

Original Article
- Clinical Features of Vascular Disorders Associated with Chronic Hepatitis Virus Infection: Nishida, N.; Kudo, M.

The easiest way to order: www.karger.com/ddi
Acute and Chronic Infections of the Gastrointestinal Tract

Editors
A. Stallmach
U. Settmacher

Contents

Editorial
• Acute and Chronic Infections of the Gastrointestinal Tract: Stallmach, A.; Settmacher, U.

Review Articles
• Calculated Antibiosis of Acute Cholangitis and Cholecystitis: Bornscheuer, T.; Schmiedel, S.
• Rational Therapy of Clostridium difficile Infections: Keller, P.M.; Weber, M.H.
• Perioperative Antibiotic Prophylaxis and Antimicrobial Therapy of Intra-Abdominal Infections: Hagel, S.; Scheuerlein, H.
• Antibiosis of Necrotizing Pancreatitis: Arft, A.; Erhart, W.; Schafmayer, C.; Held, H.-C.; Hampe, J.
• Infections and Chronic Inflammatory Bowel Disease: Kucharzik, T.; Maasar, C.
• Therapy of Liver Abscesses: Lübbert, C.; Wiegand, J.; Karlas, T.

Interdisciplinary Discussion
• Acute and Chronic Infections of the Gastrointestinal Tract: Kujath, P. (Discussion Leader)

Original Article
• Verrucous Oesophageal Carcinoma: Single Case Report and Case Series Including 15 Patients – Issues for Consideration of Therapeutic Strategies: Behrens, A.; Stolte, M.; Pech, O.; May, A.; Ell, C.

Review Article
The Journal of Innate Immunity is a bimonthly journal covering all aspects within the area of innate immunity, including evolution of the immune system, molecular biology of cells involved in innate immunity, pattern recognition and signals of ‘danger’, microbial corruption, host response and inflammation, mucosal immunity, complement and coagulation, sepsis and septic shock, molecular genomics, and development of immunotherapies. The journal publishes original research articles, short communications, reviews, commentaries and letters to the editors. In addition to regular papers, some issues feature a special section with a thematic focus.

Selected contributions
• Long-Lasting Effects of BCG Vaccination on Both Heterologous Th1/Th17 Responses and Innate Trained Immunity: Kleinijenhuis, J.; Quintin, J.; Preijers, F. (Nijmegen); Benn, C.S. (Copenhagen); Joosten, L.A.B.; Jacobs, C.; van Loenhout, J. (Nijmegen); Xavier, R.J. (Boston, Mass./Cambridge, Mass.); Aaby, P. (Copenhagen); van der Meer, J.W.M.; van Crevel, R.; Netea, M.G. (Nijmegen)
• The Anopheles Innate Immune System in the Defense against Malaria Infection: Clayton, A.M.; Dong, Y.; Dimopoulos, G. (Baltimore, Md.)
• Interferon-λ in the Context of Viral Infections: Production, Response and Therapeutic Implications: Hermant, P.; Michiels, T. (Brussels)
• The M1 Protein of Streptococcus pyogenes Triggers an Innate Uptake Mechanism into Polarized Human Endothelial Cells: Ochel, A.; Rohde, M.; Chhatwal, G.S.; Talay, S.R. (Brussels)
• Tissue-Specific Patterning of Host Innate Immune Responses by Staphylococcus aureus α-Toxin: Becker, R.E.N.; Berube, B.J.; Sampedro, G.R.; DeDent, A.C.; Bubeck Wardenburg, J. (Chicago, Ill.)
• M1 and M2 Macrophages: The Chicken and the Egg of Immunity: Mills, C.D. (Marine on St. Croix, Minn.); Ley, K. (La Jolla, Calif.)
Antimicrobial Section

Review

134 Antibiotics and Breastfeeding
de Sá Del Fiol, E.; Barberato-Filho, S.; de Cássia Bergamaschi, C.; Lopes, L.C. (Sorocaba); Gauthier, T.P. (Miami, Fla.)

Original Paper

159 Identification of a Small Benzamide Inhibitor of Influenza Virus Using a Cell-Based Screening
Shin, W.-J.; Nam, K.-Y. (Seoul); Kim, N.-D. (Daegu); Kim, S.-H.; No, K.-T.; Seong, B.-L. (Seoul)

Novel Insights from Clinical Practice

148 The Importance of Supportive Care with Tranexamic Acid in Crimean-Congo Hemorrhagic Fever
Kaya, S.; Aksoy, F.; Kenç, N.N.; Eroğlu, A.; Köksal, I. (Trabzon)

Anticancer Section

Original Papers

111 Efficacy and Safety of Carboplatin and Etoposide Combination Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma: A Retrospective Case Series

117 Microtubules and Actin Cytoskeleton of Cryptococcus neoformans as Targets for Anticancer Agents to Potentiate a Novel Approach for New Antifungals
Kopecká, M. (Brno)

122 Real-World Outcomes of Combination Chemotherapy with Trabectedin plus Pegylated Liposomal Doxorubicin in Patients with Recurrent Ovarian Cancer: A Single-Center Experience

127 Translating Clinical Evidence-Based Medicine into the Real World: Single-Center Experience with Cabazitaxel in Metastatic Prostate Cancer Patients
Moriceau, G.; Guillot, A.; Pacaut, C.; Méry, B. (Saint-Priest-en-Jarez); Falk, A.T. (Nice); Trone, J.-C.; Collard, O.; De Laroche, G.; Fournel, P.; Merrouche, Y.; Magné, N. (Saint-Priest-en-Jarez)

144 A Phase I Trial of Temsirolimus and Pemetrexed in Patients with Advanced Non-Small Cell Lung Cancer
Waqar, S.N.; Baggstrom, M.Q.; Morgensztern, D.; Williams, K.; Rigden, C.; Govindan, R. (St. Louis, Mo.)

152 Efficacy of Adjuvant Chemotherapy and Prognostic Factors for Patients with Extrabhepatic Bile Duct Cancer
Lee, H.S.; Lee, S.H.; Roh, Y.H.; Chung, M.J.; Park, J.Y.; Park, S.W.; Song, S.Y.; Chung, J.B.; Bang, S. (Seoul)